BioSpace News Archive

Irvine, California-based Fluxergy LLC, a diagnostic test company, is making a $30 million investment to expand its capability to scale production of the Fluxergy Analyzer diagnostic testing system in response to the COVID-19 pandemic.

Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China’s National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-alcoholic Steatohepatitis (NASH) indication. Ascletis has two additional drug

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020 , it has reached agreement with the FDA to resubmit its application for HETLIOZ® (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS). As previously

Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using plato TM gene therapy platform in Fabry disease trial show: 43-percent reduction in toxic metabolite plasma lyso-Gb3 one month post-treatment Significantly higher leukocyte and plasma enzyme activity three months post-treatmen

Total revenue of $26.2 million and strong growth of 26% year-over-year Record software revenue of $23.8 million, up 28% year-over-year Raised $209.6 million in net proceeds through initial public offering Conference call today, Wednesday, May 13, 2020 at 8:30 a.m. ET NEW YORK--( BUSINESS WIRE )-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeu

Pear Therapeutics, Inc. , the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual panel discussion entitled “Emerging World of Digital Therapeutics” at the SVB Leerink CybeRx Series: Digital Health – Innovators & Disruptors on Thursday, May 21 at 12:35 p.m. Eastern Time. About Pear Therapeutics Pear

Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the upcoming UBS Virtual Global Healthcare Conference, discussing Surface Oncology’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27). The presentation will take place virtually on Wednesday

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Wednesday, May 27, 2020 at 8:00 a.m. ET to report interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-sma

PetVivo Holdings, Inc. (OTCQB: PETV) Dear Stakeholders of PetVivo Holdings, Inc., PetVivo Holdings, Inc. Minneapolis MN (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to provide an update to our stakeholders. We have a number of exciting developments to share with each of you and despite the pandemic slowing the world’s economy, we believe PetVivo